Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag global-warming

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. And my estimate is that between 25,000 and 30,000 patients have been treated with those therapies globally, which does not include patients treated in clinical trials. How has the field changed in recent years?

Gene Therapy

Gene Therapy Gene Engineer Production

CSL doses first patient with haemophilia B gene therapy Hemgenix

Pharmaceutical Technology

JUNE 21, 2023

The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective. Already a big player in haemophilia treatments, CSL licensed exclusive global rights to Hemgenix from gene therapy developers uniQure back in 2021.

Gene Therapy

Gene Therapy Gene Sales Protein

Q&A: A decade on, what’s next for CAR-T therapies?

CSL doses first patient with haemophilia B gene therapy Hemgenix

Stay Connected